• Skylight Health Group (SLHG) has announced a non-brokered private placement for gross proceeds of up to $2 million
  • The company will issue up to 2,000 debenture units at $1,000 per unit
  • Each debenture will bear an annual interest rate of 8 per cent, paid quarterly in shares
  • The proceeds from the offering will be used for general working capital purposes
  • Skylight Health operates a U.S. multi-state primary care health network providing sub-specialty, allied health and laboratory/diagnostic testing
  • Skylight Health Group Inc. (SLHG) opened trading at $0.7369

Skylight Health Group (SLHG) has announced a non-brokered private placement for gross proceeds of up to $2 million.

The company will issue up to 2,000 debenture units at $1,000 per unit.

Each debenture will bear an annual interest rate of 8 per cent, paid quarterly in shares, and shall have a maturity date of February 15, 2025.

Each debenture shall be convertible into 1,111 common shares at C$0.90. Each debenture holder shall also receive 1,111 share purchase warrants. Each warrant entitles the holder to purchase one common share for a period 24 months.

The proceeds from the offering will be used for general working capital purposes.

The offering is expected to close on or about August 15, 2022.

Skylight Health operates a U.S. multi-state primary care health network providing sub-specialty, allied health and laboratory/diagnostic testing.

Skylight Health Group Inc. (SLHG) opened trading at $0.7369.


More From The Market Online

Canopy Growth fuels turnaround story with fresh capital

Canopy Growth (TSX:WEED) continues its turnaround story with a C$96.3 million exchange and subscription deal with an institutional investor.

PharmAla Biotech launches educational portal for MDMA

PharmAla Biotech (CSE:MDMA) launches its Prescribers Portal for medical practitioners to learn more about MDMA.

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.

PharmaDrug-PharmaTher Holdings JV submits clinical, regulatory package

Sairiyo Therapeutics, a PharmaDrug (CSE:PHRX) and PharmaTher Holdings (CSE:PHRM) joint venture, pursues a human clinical study in Australia.